Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years

Research output: Contribution to journalArticle

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade, as understanding of the treatment and its related toxicities has led to changes in patient selection, conditioning regimens, and post-transplant care. Older (age ≥65 years) patients are often considered unfit for transplantation; however, more recent data suggest that older patients, when selected appropriately, tolerate transplantation well. We report our institutional experience with HSCT in patients aged ≥70 years. A cohort of 22 patients underwent HSCT. Median overall survival was 5.16 years [95% confidence interval (CI): 1.5–8.7 years], and median post-transplant survival was 2.2 years (myelodysplastic syndrome: median 1.3 years, 95% CI: 4.7 months–2.2 years; acute myeloid leukemia: median not reached). Thirty-day mortality following HSCT was 9.5% (n = 2). These data provide further support for the use of HSCT in selected older patients, and highlight the impact of HSCT on overall survival among a patient cohort primarily of acute myeloid leukemia and myelodysplasia.

Original languageEnglish (US)
JournalHematology/ Oncology and Stem Cell Therapy
DOIs
StatePublished - Jan 1 2019

Fingerprint

Myelodysplastic Syndromes
Homologous Transplantation
Acute Myeloid Leukemia
Hematopoietic Stem Cell Transplantation
Transplantation
Confidence Intervals
Transplants
Survival
Hematologic Neoplasms
Patient Selection
Bone Marrow
Mortality
Therapeutics

Keywords

  • Acute Myeloid Leukemia
  • Allogeneic Stem Cell Transplant
  • Bone Marrow Transplant
  • FLT-3
  • Hypomethylating agent
  • Induction Chemotherapy
  • Leukemia
  • Myelodysplastic syndrome
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

@article{b7f6cedf896c40e3beed1005d014f7fe,
title = "Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years",
abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade, as understanding of the treatment and its related toxicities has led to changes in patient selection, conditioning regimens, and post-transplant care. Older (age ≥65 years) patients are often considered unfit for transplantation; however, more recent data suggest that older patients, when selected appropriately, tolerate transplantation well. We report our institutional experience with HSCT in patients aged ≥70 years. A cohort of 22 patients underwent HSCT. Median overall survival was 5.16 years [95{\%} confidence interval (CI): 1.5–8.7 years], and median post-transplant survival was 2.2 years (myelodysplastic syndrome: median 1.3 years, 95{\%} CI: 4.7 months–2.2 years; acute myeloid leukemia: median not reached). Thirty-day mortality following HSCT was 9.5{\%} (n = 2). These data provide further support for the use of HSCT in selected older patients, and highlight the impact of HSCT on overall survival among a patient cohort primarily of acute myeloid leukemia and myelodysplasia.",
keywords = "Acute Myeloid Leukemia, Allogeneic Stem Cell Transplant, Bone Marrow Transplant, FLT-3, Hypomethylating agent, Induction Chemotherapy, Leukemia, Myelodysplastic syndrome, Targeted therapy",
author = "Curtis Lachowiez and Cook, {Rachel J.} and Brandon Hayes-Lattin and Richard Maziarz and Uma Borate and Elie Traer and Jessica Leonard and Laura Newell and Kim-Hien Dao and Gabrielle Meyers",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.hemonc.2019.01.002",
language = "English (US)",
journal = "Hematology/ Oncology and Stem Cell Therapy",
issn = "1658-3876",
publisher = "King Faisal Specialist Hospital and Research Centre",

}

TY - JOUR

T1 - Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years

AU - Lachowiez, Curtis

AU - Cook, Rachel J.

AU - Hayes-Lattin, Brandon

AU - Maziarz, Richard

AU - Borate, Uma

AU - Traer, Elie

AU - Leonard, Jessica

AU - Newell, Laura

AU - Dao, Kim-Hien

AU - Meyers, Gabrielle

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade, as understanding of the treatment and its related toxicities has led to changes in patient selection, conditioning regimens, and post-transplant care. Older (age ≥65 years) patients are often considered unfit for transplantation; however, more recent data suggest that older patients, when selected appropriately, tolerate transplantation well. We report our institutional experience with HSCT in patients aged ≥70 years. A cohort of 22 patients underwent HSCT. Median overall survival was 5.16 years [95% confidence interval (CI): 1.5–8.7 years], and median post-transplant survival was 2.2 years (myelodysplastic syndrome: median 1.3 years, 95% CI: 4.7 months–2.2 years; acute myeloid leukemia: median not reached). Thirty-day mortality following HSCT was 9.5% (n = 2). These data provide further support for the use of HSCT in selected older patients, and highlight the impact of HSCT on overall survival among a patient cohort primarily of acute myeloid leukemia and myelodysplasia.

AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is an integral therapy for patients with hematological malignancies, myelodysplasia, and bone marrow failure. Its use has been increasing over the past decade, as understanding of the treatment and its related toxicities has led to changes in patient selection, conditioning regimens, and post-transplant care. Older (age ≥65 years) patients are often considered unfit for transplantation; however, more recent data suggest that older patients, when selected appropriately, tolerate transplantation well. We report our institutional experience with HSCT in patients aged ≥70 years. A cohort of 22 patients underwent HSCT. Median overall survival was 5.16 years [95% confidence interval (CI): 1.5–8.7 years], and median post-transplant survival was 2.2 years (myelodysplastic syndrome: median 1.3 years, 95% CI: 4.7 months–2.2 years; acute myeloid leukemia: median not reached). Thirty-day mortality following HSCT was 9.5% (n = 2). These data provide further support for the use of HSCT in selected older patients, and highlight the impact of HSCT on overall survival among a patient cohort primarily of acute myeloid leukemia and myelodysplasia.

KW - Acute Myeloid Leukemia

KW - Allogeneic Stem Cell Transplant

KW - Bone Marrow Transplant

KW - FLT-3

KW - Hypomethylating agent

KW - Induction Chemotherapy

KW - Leukemia

KW - Myelodysplastic syndrome

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85062405205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062405205&partnerID=8YFLogxK

U2 - 10.1016/j.hemonc.2019.01.002

DO - 10.1016/j.hemonc.2019.01.002

M3 - Article

AN - SCOPUS:85062405205

JO - Hematology/ Oncology and Stem Cell Therapy

JF - Hematology/ Oncology and Stem Cell Therapy

SN - 1658-3876

ER -